File an Investigational New Drug application for TYRA-200
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Nov 2021
- Due
- 31 Dec 2022
- Delivered
- March 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“TYRA anticipates filing an Investigational New Drug application (IND) for TYRA-200 with the U.S. Food and Drug Administration in the second half of 2022.”
What we found
Evidence strength A What the grades mean
The company announced in March 2023 that the FDA cleared its IND for TYRA-200, which occurred after the second half of 2022 deadline.
-
A Tyra Biosciences, Inc. 8-K filed 2023-03-22
“In March 2023, TYRA announced that the FDA cleared its IND to proceed with a Phase 1 clinical study of TYRA-200” ✓ confirmed on the page
Market reaction: the shares moved +0.7% against the S&P 500 over the three sessions around the disclosure (21 Mar 2023 to 24 Mar 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +731 days
- 5 versions
-
Version 1 · original · stated 3 Nov 2021
Deadline 31 Dec 2022 (“in the second half of 2022”) · wording expected
-
Version 2 · stated 3 Mar 2022
Deadline 30 Jun 2022 (“mid-2022”) · wording firm
“TYRA remains on track to submit an IND with the U.S. FDA for TYRA-300 in mid-2022”
-
Version 3 · stated 3 Mar 2022
Deadline 31 Dec 2022 (“second half of 2022”)
“and for TYRA-200 in the second half of 2022.”
-
Version 4 · stated 5 May 2022
Deadline 30 Jun 2022 (“mid-2022”)
“submit an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for TYRA-300 in mid-2022”
-
Version 5 · stated 4 May 2023
Deadline 31 Dec 2024 (“in 2024”) · wording firm
“TYRA is on track to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to enable a Phase 2 study of TYRA-300 in pediatric achondroplasia in 2024.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- File
- Deliverable
- Investigational New Drug application for TYRA-200
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Tyra Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-TYRA-002058 · Corrections policy